-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Agaritide API Approved by Shijiazhuang Sihua Pharmaceutical Group
Category:
TIME：2022-09-07
【SUMMARY】
Recently, agagatran, submitted by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed dosage forms.
Recently, agatibant, submitted by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed dosage forms.
According to available information, argatroban is a next-generation anticoagulant belonging to the class of small-molecule direct thrombin inhibitors. Its formulations are primarily used in clinical practice for the treatment of peripheral arterial occlusive disease and for the prevention or management of arterial thrombosis.
Focusing on a business development strategy centered on “active pharmaceutical ingredients plus finished dosage forms,” Shijiazhuang Sihua Pharmaceutical Group has vigorously extended, supplemented, and strengthened its core industrial chains, achieving significant progress in the R&D of specialty formulations and APIs. Since the beginning of this year, the company has obtained a total of 26 product approvals, including 16 finished dosage form varieties and 10 API varieties, with four of the finished dosage form varieties being the first to receive approval among domestic pharmaceutical companies.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
Business License
